Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

ABSTRACT:

Purpose

Most treatments for patients with metastatic melanoma have a low rate of complete regression and thus overall survival in these patients is poor. We investigated the ability of adoptive cell transfer utilizing autologous tumor-infiltrating lymphocytes (TIL) to mediate durable complete regressions in heavily pretreated patients with metastatic melanoma.

Experimental design

Ninety-three patients with measurable metastatic melanoma were treated with the adoptive transfer of autologous TILs administered in conjunction with interleukin-2 following a lymphodepleting preparative regimen on three sequential clinical trials. Ninety-five percent of these patients had progressive disease following a prior systemic treatment. Median potential follow-up was 62 months.

Results<

SUBMITTER: Rosenberg SA 

PROVIDER: S-EPMC3131487 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature